Houston, Texas. June 6, 2020 – Asylia Therapeutics (“Asylia”), a Texas-based, privately held, development-stage biopharmaceutical company developing novel immune modulating therapies for cancer, autoimmune, and infectious diseases has officially landed at Johnson & Johnson Innovation – JLABS in the Texas Medical Center (JLABS @ TMC). With over 34,000 square feet of common, wet lab, and office space, the Houston site boasts the largest JLABS footprint in the US.
Asylia recently announced its exclusive worldwide license agreement with The University of Texas MD Anderson Cancer Center and news of a $3 million Seed Award for Product Development Research from the Cancer Prevention & Research Institute of Texas (CPRIT).
“Asylia is pleased to join a diverse group of companies doing good work to improve the lives of patients. Moving into JLABS @TMC was an easy decision given their model to enable talented scientists in the region to take their innovations to the next level and helping entrepreneurs advance science with the potential to become transformational solutions for patients,” shared Jeno Gyuris, PhD, Asylia’s Executive Vice President and Chief Scientific Officer.
Asylia’s lead product, ASY-77A, is a novel antibody that targets the extracellular form of Heat shock protein (HSP)-70 that works by increasing the ability of dendritic cells, which are key to initiating immune reactions, to better recognize the presence of cancer cells. As a result, T-cells become activated to kill cancer cells. Notably, ASY-77A has produced complete regression of various cancer types in pre-clinical models including solid tumors such as breast and colon cancer, and blood-related cancers like multiple myeloma.
About Asylia Therapeutics
Asylia Therapeutics is a private, development-stage biotechnology company advancing novel immune modulating therapies for cancer, autoimmune, and infectious diseases, which collectively impact tens of millions of Americans annually. Founded in 2019 by three prominent physician-scientists at MD Anderson Cancer Center (Robert Orlowski, MD, Ph.D., professor & past chair of the Department of Lymphoma & Myeloma, Ronald A. DePinho, MD, professor & past president and Richard J. Jones, Ph.D., assistant professor in the Department of Lymphoma and Myeloma), Asylia is based in Houston, Texas. The company’s platform centers on a drug pipeline capable of modulating antigen presentation to the immune system which has, to date, produced unprecedented anti-tumor responses across multiple cancer models.
For more information please contact us.
